Mission
Guiding Principles
FOCUSED ON ADVANCING GENETIC MEDICINES FOR NEUROMUSCULAR AND CARDIAC RARE DISEASES
Solid Biosciences is a precision genetic medicine company focused on advancing a portfolio of gene therapy candidates targeting rare neuromuscular and cardiac diseases, including Duchenne muscular dystrophy (Duchenne), Friedreich’s ataxia (FA), catecholaminergic polymorphic ventricular tachycardia (CPVT), TNNT2-mediated dilated cardiomyopathy, BAG3-mediated dilated cardiomyopathy, and additional fatal, genetic cardiac diseases. The Company is also focused on developing innovative libraries of genetic regulators and other enabling technologies with promising potential to significantly impact gene therapy delivery cross-industry. Solid is advancing its diverse pipeline and delivery platform in the pursuit of uniting experts in science, technology, disease management, and care. Patient-focused and founded by those directly impacted by Duchenne, Solid’s mission is to improve the daily lives of patients living with devastating rare diseases.
see "attributes' tool for settings for this row
Guiding Principles
Solid is purpose-built to identify and develop the most promising approaches to address these diseases at all stages.
FOCUSED
We are focused on developing transformative treatments to improve the lives of patients with neuromuscular and cardiac diseases
PATIENT CENTRIC
We start with patients and their unmet needs.
COLLABORATIVE
We are working collectively with all stakeholders — industry, academia, government, and community — to advance our gene therapy candidates to better understand their potential to benefit patients.
CENTER OF EXCELLENCE
We are a catalyst bringing together the best knowledge to address all aspects of these diseases.